Takeda Pharmaceutical Company Limited (TAK) Investment Research Dashboard
About Takeda Pharmaceutical Company Limited (TAK) stock analysis
Get live TAK stock price $17.52, comprehensive Takeda Pharmaceutical Company Limited stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time TAK stock data and investment insights.
Loading chart data...
Takeda Pharmaceutical Company Limited (TAK) Overview
Takeda Pharmaceutical Company Limited (TAK) is a publicly traded company in the Healthcare sector , specifically within the Drug Manufacturers - Specialty & Generic industry . As of the latest trading session, TAK trades at $17.52 with a market capitalization of 55.74B . Over the past 52 weeks, TAK has traded between $12.99 and $18.90 , with the current price positioned at approximately 77% of ...
Key Takeaways
- Operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic)
- Market cap: 55.74B
- Current price: $17.52
- 52-week range: $12.99 - $18.90
- P/E ratio: 12.60
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vas...
Company Information
- CEO
- Julie So-Young Kim
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 47029
Contact Information
- Website
- https://www.takeda.com
- Address
- 1-1, Nihonbashi-Honcho 2-chome
- Country
- JP
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 12.6)
✓ Lower volatility stock (Beta: 0.09) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Takeda Pharmaceutical Company Limited shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Takeda Pharmaceutical Company Limited
- ⚠Investors should consider how Takeda Pharmaceutical Company Limited fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
55.74B
P/E Ratio (TTM)
12.60
Beta
0.09
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare TAK with peer companies:
- Price
- $140.60+1.97% (1D)
- Market cap
- 39.71B
- Price
- $69.11+2.72% (1D)
- Market cap
- 33.70B
- Price
- $166.34+4.67% (1D)
- Market cap
- 60.26B
- Price
- $232.51+1.38% (1D)
- Market cap
- 54.46B
- Price
- $83.68+0.77% (1D)
- Market cap
- 48.18B
- Price
- $10.27+3.27% (1D)
- Market cap
- 45.23B
- Price
- $104.13-0.57% (1D)
- Market cap
- 22.57B
- Price
- $243.31+14.11% (1D)
- Market cap
- 40.61B
- Price
- $208.96+2.90% (1D)
- Market cap
- 30.31B
- Price
- $201.20+3.47% (1D)
- Market cap
- 32.68B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
78/100 ⭐⭐⭐⭐⭐
- Overall
- +0.7%
- NYSE
- +0.6%
- NASDAQ
- +0.7%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +2.2% | +3.1% | +4.3% | 19.3 | 98/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.7% | +1.3% | +1.6% | 24.1 | 78/100⭐⭐⭐⭐⭐ |
| Communication Services | +1.4% | -0.7% | +2.9% | 22.2 | 74/100⭐⭐⭐⭐⭐ |
| Consumer Defensive | -0.2% | +1.8% | +0.7% | 29.8 | 64/100⭐⭐⭐⭐ |
| Basic Materials | +0.4% | +1.2% | -0.2% | 25.2 | 61/100⭐⭐⭐⭐ |
| Real Estate | -0.5% | +0.0% | -2.4% | 29.2 | 46/100⭐⭐⭐ |
| Energy | -2.1% | -3.7% | -4.1% | 19.1 | 39/100⭐⭐ |
| Utilities | -1.0% | +0.0% | -4.4% | 26.8 | 35/100⭐⭐ |
| Industrials | +0.6% | +0.4% | -9.9% | 30.1 | 23/100⭐ |
| Consumer Cyclical | +0.5% | -1.5% | -5.8% | 43.0 | 18/100⭐ |
| Technology | +0.6% | -1.6% | -7.2% | 40.7 | 15/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.